Bicalutamide (Casodex) - Comprehensive Research Paper

Document Information

• Created: 2025-12-26
• Purpose: Clinical reference for hormone therapy product knowledge
• Paper Number: 55 of 76 (Anti-Androgens: Nonsteroidal - First Generation)

1. Summary

Bicalutamide is a first-generation nonsteroidal antiandrogen (NSAA) marketed primarily under the brand name Casodex. FDA-approved on October 4, 1995, it represents one of the three first-generation NSAAs (alongside flutamide and nilutamide) but distinguishes itself through superior tolerability, reduced hepatotoxicity compared to flutamide, and a significantly longer half-life of approximately 6 days enabling once-daily dosing.

The medication competitively inhibits androgen receptor binding, blocking testosterone and dihydrotestosterone (DHT) from exerting their biological effects at target tissues. Unlike steroidal antiandrogens such as cyproterone acetate, bicalutamide has no progestogenic, glucocorticoid, or mineralocorticoid activity and does not directly suppress gonadotropin secretion.

Bicalutamide's FDA-approved indication is narrowly defined: combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for Stage D2 metastatic prostate cancer at a dose of 50 mg daily. However, off-label use has expanded significantly, particularly in transgender hormone therapy where doses of 25-50 mg daily are employed for androgen blockade in feminizing regimens.

The medication is included on the World Health Organization's List of Essential Medicines and is available as a generic medication, making it accessible globally. Its favorable pharmacokinetic profile and relative safety compared to earlier antiandrogens have contributed to its widespread adoption, though concerns about rare but serious hepatotoxicity warrant appropriate monitoring protocols.

Goal Relevance:

• Managing advanced prostate cancer to improve quality of life and slow disease progression
• Supporting transgender individuals in feminizing hormone therapy by reducing testosterone effects
• Addressing unwanted male-pattern hair growth in women when other treatments are not suitable
• Enhancing treatment plans for metastatic prostate cancer by combining with other hormone therapies
• Seeking alternatives to traditional antiandrogens with fewer side effects for prostate cancer management

1A. Goal Archetype Integration

Anti-Androgen Goal Archetype

Primary Goal Classification: Androgen Receptor Blockade

Bicalutamide serves users whose primary therapeutic goal is to antagonize androgen action at the receptor level without directly suppressing testosterone production. This "pure" antiandrogen approach is distinct from agents that work through hormonal suppression.

Archetype Characteristics:

• Competitive AR antagonism without hormonal activity
• Peripheral blockade preserves gonadal function (when used as monotherapy)
• No progestogenic side effects (mood changes, weight gain)
• No glucocorticoid effects (metabolic disruption, adrenal suppression)

When This Archetype Applies:

• User wants androgen blockade without central hormonal suppression
• User has contraindications to progestins or GnRH analogs
• User prefers once-daily oral therapy over injections
• User values preservation of some testicular function

Prostate Cancer Goal Archetype

Primary Goal: Combined Androgen Blockade (CAB) for Maximum Tumor Suppression

For prostate cancer patients, bicalutamide fits the "maximal androgen blockade" archetype - combining peripheral AR antagonism with central testosterone suppression via LHRH analog.

Archetype Characteristics:

• Two-pronged attack: suppress production + block receptor
• Targets both testicular and adrenal androgens
• Addresses "flare" phenomenon when initiating LHRH analogs
• Used in metastatic disease requiring aggressive intervention

Treatment Goals Within Archetype:

When This Archetype Applies:

• Stage D2 metastatic prostate cancer (FDA-approved indication)
• Initiating LHRH analog (covers testosterone flare)
• Castration-sensitive disease requiring maximal blockade
• Palliative intent with emphasis on quality of life

Feminizing HRT Goal Archetype

Primary Goal: Androgen Suppression/Blockade for Gender Affirmation

For transgender women and transfeminine individuals, bicalutamide serves the "feminization" archetype by blocking testosterone effects at target tissues.

Archetype Characteristics:

• Blocks masculinizing effects of testosterone
• Allows estrogen to dominate hormonal milieu
• Preserves fertility potential (unlike GnRH analogs)
• Minimal metabolic disruption compared to spironolactone

Treatment Goals Within Archetype:

Feminization Timeline Expectations:

When This Archetype Applies:

• Transfeminine individual seeking androgen blockade
• Spironolactone-intolerant (electrolyte issues, hypotension)
• Preference for non-diuretic antiandrogen
• Fertility preservation desired
• Adolescent with gender dysphoria (under specialist care)

Goal Archetype Comparison Matrix

2. Mechanism of Action

Primary Mechanism: Androgen Receptor Antagonism

Bicalutamide functions as a competitive, selective antagonist at the androgen receptor (AR). The medication binds to the ligand-binding domain of the AR, preventing endogenous androgens (testosterone and DHT) from activating the receptor.

Molecular Binding Characteristics:

• Bicalutamide binds to the cytosolic androgen receptor
• Produces conformational distortion of the co-activator binding site
• Prevents proper nuclear translocation of the receptor-ligand complex
• Blocks gene transcription normally initiated by androgen-receptor activation

Structural Classification

Bicalutamide belongs to the diarylpropionamide class of nonsteroidal antiandrogens:

• Chemical structure: Diarylpropionamide derivative
• Related compounds: Flutamide (monoarylpropionamide), nilutamide (hydantoin)
• Stereochemistry: Administered as a racemic mixture; the (R)-enantiomer is the active form

Pure Antiandrogen Properties

Unlike steroidal antiandrogens (cyproterone acetate, spironolactone), bicalutamide is a "pure" antiandrogen:

• No progestogenic activity
• No glucocorticoid activity
• No mineralocorticoid activity
• No direct suppression of gonadotropin secretion

Consequences of Peripheral AR Blockade

When used as monotherapy (without LHRH analog), bicalutamide's peripheral AR blockade disrupts the hypothalamic-pituitary-gonadal feedback loop:

• Hypothalamus cannot detect testosterone action
• Increased LH and FSH secretion
• Elevated serum testosterone levels (paradoxically)
• Increased estrogen through peripheral aromatization
• This explains gynecomastia/breast tenderness in monotherapy

Receptor Binding Affinity

Bicalutamide demonstrates:

• 2-4 times lower binding affinity than DHT at the AR
• Higher binding affinity than flutamide
• Longer receptor occupancy due to slow dissociation

3. FDA-Approved Indications

Approved Indication

Stage D2 Metastatic Carcinoma of the Prostate

• Approved: October 4, 1995 (accelerated approval)
• Use: In combination with a luteinizing hormone-releasing hormone (LHRH) analog
• Stage D2 represents metastatic disease with distant metastases

Regulatory Notes

Initial Accelerated Approval: The 1995 FDA approval was granted under accelerated approval based on surrogate endpoints (PSA response). This reflected the urgent need for effective prostate cancer treatments and the favorable safety profile compared to available alternatives.

Early Prostate Cancer Application (Not FDA-Approved): Bicalutamide at higher doses (150 mg daily) was studied for early prostate cancer in the Early Prostate Cancer (EPC) program. While approved in some countries for this indication:

• NOT approved by FDA for early prostate cancer
• 2002: FDA rejected application for early prostate cancer indication
• Concern about overall survival benefit not demonstrated in localized disease

Current Labeling Requirements

The FDA-approved label specifies:

• Dose: 50 mg once daily
• Must be used in combination with LHRH analog
• Not indicated for monotherapy in any setting
• Not indicated for non-metastatic prostate cancer

4. Dosing and Administration

FDA-Approved Dosing (Prostate Cancer)

Standard Dose:

• 50 mg orally once daily
• Given in combination with LHRH analog (leuprolide, goserelin, etc.)
• Treatment initiated simultaneously with LHRH analog

Administration:

• Take at the same time each day
• May be taken with or without food
• Tablets should be swallowed whole

Off-Label Dosing Patterns

Transgender Feminizing Therapy:

• Typical dose: 25-50 mg daily
• Often used in combination with estradiol
• Some protocols start at 25 mg and titrate based on response
• Lower doses may be sufficient due to different therapeutic goals

Hirsutism/Androgenic Conditions (Off-Label):

• 25-50 mg daily has been studied
• Used when spironolactone is contraindicated or ineffective

Dosing Considerations

No Dose Adjustment Required For:

• Mild to moderate renal impairment
• Age alone (though elderly may have altered pharmacokinetics)

Caution Required For:

• Hepatic impairment (contraindicated in moderate-severe impairment)
• Patients on concurrent hepatotoxic medications

Missed Dose:

• Take as soon as remembered
• If close to next dose, skip missed dose
• Do not double up doses

Treatment Duration

Prostate Cancer:

• Continue until disease progression
• Treatment is indefinite in responding patients
• Discontinuation only upon progression or intolerable side effects

Transgender Therapy:

• Duration individualized
• May be discontinued if orchiectomy is performed
• Some patients continue long-term if surgery is not pursued

4A. Age-Stratified Dosing

Pediatric/Adolescent (Under 18)

Clinical Context:

• NOT FDA-approved for pediatric use
• Used off-label in specialized gender clinics for adolescents with gender dysphoria
• WPATH SOC8 notes sparse data and lacking safety information
• Requires parental/guardian consent and multidisciplinary team oversight

Recommended Dosing:

Special Considerations:

• Growth plate status should be assessed (may affect timing)
• Psychological maturity assessment required
• Lower doses preferred given limited safety data
• More frequent LFT monitoring (every 4-6 weeks initially)
• Single case report of hepatotoxicity in transgender adolescent at 50 mg
• Consider baseline bone density assessment

Monitoring Frequency (Adolescents):

• LFTs: Baseline, then every 4-6 weeks for 3 months, then monthly
• Clinical assessment: Monthly initially
• Hormone levels: Every 3 months
• Growth monitoring: Per standard pediatric protocols

Young Adult (18-35)

Clinical Context:

• Most transgender patients fall in this age range
• Generally healthiest population with lowest hepatotoxicity risk
• 2024 case series of 24 transgender adults showed favorable safety profile

Recommended Dosing:

Special Considerations:

• Fertility counseling recommended before initiation
• Sperm banking discussion if applicable
• Standard monitoring protocol appropriate
• May use full doses given lower baseline hepatotoxicity risk

Middle-Aged Adult (36-64)

Clinical Context:

• Prostate cancer may emerge as indication in later years of this range
• Transgender patients may have been on therapy for years
• Metabolic considerations become more relevant

Recommended Dosing:

Special Considerations:

• Increased baseline cardiovascular risk assessment needed
• Metabolic syndrome screening recommended
• Drug interaction review critical (polypharmacy more common)
• Consider baseline hepatic function more carefully

Geriatric (65+)

Clinical Context:

• Primary prostate cancer population
• Higher prevalence of hepatic impairment
• Greater polypharmacy risk
• May have altered pharmacokinetics (prolonged half-life)

Recommended Dosing:

Special Considerations:

• More frequent LFT monitoring recommended
• Comprehensive drug interaction review essential
• Renal function assessment (even though no formal adjustment)
• Fall risk assessment (general geriatric concern)
• Cardiovascular risk already elevated at baseline
• Quality of life considerations paramount

Geriatric Monitoring Protocol:

• LFTs: Baseline, weeks 2, 4, 8, 12, then monthly for 6 months, then quarterly
• Renal function: Baseline and every 3 months
• CBC: Baseline and every 3-6 months
• Comprehensive metabolic panel: Every 3 months

Age-Stratified Dosing Summary Table

*Consider 25 mg start if hepatic/renal concerns

5. Pharmacokinetics

Absorption

• Bioavailability: Well absorbed after oral administration
• Time to Peak (Tmax): Approximately 31 hours for active (R)-enantiomer
• Food Effect: No clinically significant effect on absorption
• Steady State: Achieved after approximately 4 weeks of daily dosing due to long half-life

Distribution

• Protein Binding: Highly protein bound (96%)
• Primary Binding Protein: Albumin
• Volume of Distribution: Not extensively distributed outside plasma
• Tissue Penetration: Achieves therapeutic concentrations in prostate tissue

Metabolism

• Primary Route: Hepatic metabolism via cytochrome P450 system
• Major Enzyme: CYP3A4 (primary), with minor contribution from CYP2C9
• Metabolites:
  • (S)-enantiomer: Inactive, rapidly glucuronidated and eliminated
  • (R)-enantiomer: Active, undergoes oxidation then glucuronidation
• Active Metabolite: Parent compound is the primary active species

Elimination

• Half-Life (R-enantiomer): Approximately 5.8-6 days (one week)
• Half-Life (S-enantiomer): Approximately 1 day
• Excretion Routes:
  • Urine: ~36% (glucuronide conjugates)
  • Feces: ~43%
• Total Clearance: Approximately 0.32 L/hr

Clinical Implications of Long Half-Life

The ~6-day half-life has important clinical implications:

1. Once-daily dosing: Convenient administration schedule
2. Slow onset: Takes 4 weeks to reach steady state
3. Slow offset: Effects persist for weeks after discontinuation
4. Missed doses: Single missed doses have minimal impact on drug levels
5. Drug accumulation: Approximately 10-fold accumulation at steady state

Pharmacokinetic Comparison with Other NSAAs

6. Side Effects and Adverse Reactions

Common Side Effects (≥10% Incidence)

When Used with LHRH Analog (Combined Androgen Blockade):

• Hot flashes (53%)
• Pain (general, including tumor pain) (35%)
• Asthenia/fatigue (22%)
• Back pain (15%)
• Constipation (17%)
• Infection (18%)
• Pelvic pain (21%)
• Peripheral edema (13%)

When Used as Monotherapy (150 mg studies):

• Gynecomastia (66-73%)
• Breast pain/tenderness (68-73%)
• Hot flashes (less common than with LHRH analog)
• Sexual dysfunction

Serious Adverse Reactions

Hepatotoxicity:

• Marked increases in liver enzymes: ~1% of patients
• Hepatitis requiring discontinuation: ~1%
• Rare cases of hepatic failure and death reported
• Typically occurs within first 3-4 months of therapy
• Risk factors: Pre-existing liver disease, concurrent hepatotoxic drugs

Cardiovascular:

• Increased risk of myocardial infarction (in early prostate cancer studies)
• QT prolongation (reported rarely)

Interstitial Lung Disease:

• Rare but reported in post-marketing surveillance
• Can be fatal
• More commonly associated with nilutamide than bicalutamide

Endocrine Effects

Gynecomastia and Breast Changes:

• More prominent with monotherapy than combination therapy
• Results from increased estrogen:androgen ratio
• Prophylactic breast irradiation can reduce incidence
• Tamoxifen can treat or prevent

Sexual Function:

• Decreased libido
• Erectile dysfunction
• These effects are largely attributable to LHRH analog when used in combination

Gastrointestinal

• Nausea (15%)
• Diarrhea (12%)
• Constipation (17%)
• Abdominal pain

Laboratory Abnormalities

• Elevated hepatic transaminases
• Anemia (7-11%)
• Increased BUN
• Hyperglycemia

Comparison with Other First-Generation NSAAs

7. Drug Interactions

Cytochrome P450 Interactions

CYP3A4 Substrates:

• Bicalutamide is metabolized primarily by CYP3A4
• CYP3A4 inhibitors may increase bicalutamide exposure
• CYP3A4 inducers may decrease bicalutamide exposure

Clinically Significant Interactions:

Warfarin (Major):

• Bicalutamide may displace R-warfarin from protein binding
• Can increase INR and bleeding risk
• Close monitoring of PT/INR required
• Dose adjustment of warfarin may be necessary
• FDA label carries specific warning

Midazolam:

• Bicalutamide may increase midazolam exposure
• Clinical significance uncertain but caution advised

Protein Binding Displacement

Due to high protein binding (96%), bicalutamide may interact with other highly protein-bound drugs:

• Warfarin (as noted above)
• Phenytoin
• Other highly bound drugs

Drugs That May Increase Hepatotoxicity Risk

Concurrent use with hepatotoxic agents may increase liver injury risk:

• Acetaminophen (high doses)
• Statins
• Azole antifungals
• Methotrexate
• Other antiandrogens

Hepatotoxicity Monitoring in Drug Interactions

High-Risk Combinations Requiring Enhanced Monitoring:

Hepatotoxicity Risk Stratification Algorithm:

Step 1: Assess Baseline Risk
├── Pre-existing liver disease → Contraindicated
├── History of drug-induced hepatitis → High risk, consider alternatives
├── Active hepatitis B/C → Contraindicated without specialist
├── Elevated baseline LFTs → Enhanced monitoring
└── Normal baseline → Standard monitoring

Step 2: Evaluate Concurrent Medications
├── 0 hepatotoxic drugs → Standard protocol
├── 1 hepatotoxic drug → Enhanced monitoring (2x frequency)
├── 2+ hepatotoxic drugs → Consider risk-benefit carefully
└── High-risk combination → Weekly LFTs initially

Step 3: Age Adjustment
├── <18 years → Add 50% more frequent monitoring
├── 18-65 years → Per step 1-2
└── >65 years → Add 25% more frequent monitoring

Action Thresholds for LFT Elevations:

Symptoms Warranting Immediate LFT Check:

• Right upper quadrant pain or tenderness
• Unexplained nausea, vomiting, or anorexia
• Dark urine (tea-colored)
• Pale/clay-colored stools
• Jaundice (skin or scleral icterus)
• Unexplained fatigue or malaise
• Pruritus without rash

Drugs Affecting QT Interval

Though bicalutamide's QT effect is minimal, caution with:

• Class IA antiarrhythmics (quinidine, procainamide)
• Class III antiarrhythmics (amiodarone, sotalol)
• Other QT-prolonging drugs

Drug-Food Interactions

• No significant food interactions
• Grapefruit juice (CYP3A4 inhibitor): Theoretical increased exposure, but not clinically studied

Drug-Lab Interactions

• May affect PSA measurements (expected therapeutic effect)
• May affect liver function tests

8. Contraindications

Absolute Contraindications

Hypersensitivity:

• Known hypersensitivity to bicalutamide or any component
• Cross-reactivity with other NSAAs not established but possible

Pregnancy:

• Category X in combination products
• Absolutely contraindicated in women who are or may become pregnant
• May cause fetal harm
• Animal studies show feminization of male fetuses

Pediatric Use (General):

• Not indicated for use in children
• Safety and efficacy not established in pediatric populations
• Exception: Off-label use in adolescents for gender dysphoria in specialized centers with appropriate monitoring

Relative Contraindications

Hepatic Impairment:

• Contraindicated in moderate to severe hepatic impairment
• Use with extreme caution in mild hepatic impairment
• More frequent monitoring required

Pre-existing Liver Disease:

• Active hepatitis
• Cirrhosis
• History of drug-induced hepatotoxicity

Warnings and Precautions

Hepatotoxicity Monitoring:

• Baseline liver function tests required
• Monitor at regular intervals for first 4 months
• Periodic monitoring thereafter
• Discontinue if ALT rises above 2x ULN or jaundice develops

Use in Women:

• Not indicated for women (FDA-approved indication is prostate cancer)
• Off-label use in transgender individuals requires careful risk-benefit assessment
• Ensure pregnancy testing and contraception in relevant populations

Diabetes/Glucose Intolerance:

• May affect glycemic control
• Monitor blood glucose in diabetic patients

9. Special Populations

Geriatric Patients

Pharmacokinetic Considerations:

• Primary patient population for prostate cancer indication
• Half-life may be prolonged in elderly
• No specific dose adjustment recommended
• More frequent monitoring of liver function advised

Clinical Considerations:

• Higher baseline cardiovascular risk
• May have pre-existing hepatic dysfunction
• Polypharmacy concerns (drug interactions)

Pediatric Patients

• Not FDA-approved for pediatric use
• Safety and efficacy not established

Off-Label Use (Gender Dysphoria):

• Used in some adolescent gender clinics
• 2024 case series of 24 transgender individuals showed median ALT of 20 IU/L
• Single case report of hepatotoxicity in transgender adolescent (50 mg daily)
• WPATH SOC8 notes sparse data and lacking safety information
• Lower doses (25 mg) may be appropriate
• Requires careful monitoring and informed consent

Hepatic Impairment

Recommendations:

• Mild impairment: Use with caution, frequent LFT monitoring
• Moderate impairment: Contraindicated
• Severe impairment: Contraindicated
• Active hepatic disease: Contraindicated

Monitoring in Hepatic Impairment:

• Baseline LFTs before initiation
• LFTs every 2 weeks for first 2 months
• Monthly thereafter
• Immediate discontinuation if significant elevations

Renal Impairment

• No dose adjustment required for mild to moderate impairment
• Severe impairment: Limited data, use with caution
• Dialysis: Not studied, drug is highly protein-bound

Transgender Individuals

Clinical Considerations:

• Growing evidence base from 2024 studies
• Retrospective cohort data suggests no increased transaminase elevation compared to other antiandrogens
• Lower doses typically used (25-50 mg) compared to prostate cancer
• Younger, healthier population may have lower hepatotoxicity risk
• Standard monitoring protocols still recommended

2024 Research Findings:

• Case series of 24 transgender adults showed no signal of hepatotoxicity
• Median serum ALT 20 (13-29) IU/L within normal limits
• Only 1 individual had grade 1 toxicity (in setting of intercurrent condition)

10. Monitoring Parameters

Pre-Treatment Baseline

Required:

• Liver function tests (AST, ALT, alkaline phosphatase, bilirubin)
• PSA (prostate cancer patients)
• Complete blood count

Recommended:

• Renal function (BUN, creatinine)
• Blood glucose
• Baseline ECG (if cardiac history)

Hepatic Monitoring Protocol

FDA-Recommended Schedule:

1. Baseline (before initiation)
2. Regular intervals during first 4 months (monthly recommended)
3. Periodically thereafter (every 3-6 months)

Action Thresholds:

• ALT/AST >2x ULN: Consider discontinuation
• ALT/AST >3x ULN with symptoms: Discontinue immediately
• Any elevation with jaundice: Discontinue immediately

Symptoms Requiring Immediate Evaluation:

• Right upper quadrant pain
• Unexplained nausea/vomiting
• Dark urine
• Jaundice (yellowing of skin/eyes)
• Unexplained fatigue

Prostate Cancer Monitoring

Disease Response:

• PSA levels (frequency per oncology protocol)
• Imaging studies as clinically indicated
• Bone scans if metastatic disease

Side Effect Monitoring:

• Hot flash frequency/severity
• Sexual function assessment
• Gynecomastia evaluation
• Quality of life assessments

Transgender Therapy Monitoring

Hormone Levels:

• Testosterone levels (goal: female reference range)
• Estradiol levels (if on concurrent estrogen)

Safety Monitoring:

• LFTs: Monthly for first 3 months, then quarterly
• CBC: Baseline and annually
• Metabolic panel: Every 3-6 months initially

Clinical Assessment:

• Breast development
• Facial hair reduction
• Skin/complexion changes
• Psychological well-being

Long-Term Monitoring

Annual Assessments:

• Complete metabolic panel
• Liver function tests
• Lipid panel
• Bone density (if on long-term therapy without estrogen supplementation)

10A. Bloodwork Impact

Liver Function Tests (LFTs) - Critical Monitoring

Hepatic monitoring is the cornerstone of bicalutamide safety surveillance. Understanding expected vs. concerning patterns is essential.

Primary LFT Markers:

Expected vs. Pathological LFT Changes:

Timeline of Hepatotoxicity Risk:

Week 0-4:   Highest risk period (most cases manifest here)
Week 4-12:  Continued vigilance; still elevated risk
Week 12-24: Risk decreasing but not negligible
Month 6+:   Rare but still possible; maintain quarterly LFTs

2024 Transgender Data (Reference Values):

• Case series of 24 transgender adults on bicalutamide
• Median ALT: 20 IU/L (IQR 13-29)
• All within normal limits except 1 grade 1 toxicity (intercurrent illness)
• Supports favorable safety profile in younger, healthier population

Testosterone and Related Hormones

Effect on Testosterone Levels:

Bicalutamide's impact on testosterone varies dramatically based on whether it's used as monotherapy or combined with LHRH analogs.

Monotherapy (Pure AR Blockade):

Combined Therapy (With LHRH Analog or Estrogen):

Testosterone Monitoring in Feminizing HRT:

Clinical Interpretation of Hormone Levels:

Scenario: Patient on Bicalutamide Monotherapy
├── High T + clinical response → Effective AR blockade
├── High T + poor response → Consider dose increase or add E2
└── Stable T, good response → Continue current regimen

Scenario: Patient on Bicalutamide + Estradiol
├── T >100 ng/dL → Consider adding GnRH analog or increasing E2
├── T 50-100 ng/dL → Acceptable; monitor response
├── T <50 ng/dL → Optimal suppression achieved
└── E2 <100 pg/mL → May need to increase estradiol dose

Other Laboratory Parameters

Complete Blood Count (CBC):

Expected hemoglobin changes in feminizing HRT:

• Baseline male range: 14-18 g/dL
• Expected on therapy: 12-16 g/dL (moves toward female range)

Metabolic Panel:

Lipid Panel:

Prostate-Specific Antigen (PSA) - Prostate Cancer Patients:

Bloodwork Summary by Indication

Feminizing HRT Panel:

Baseline and every 3 months initially:
├── Comprehensive Metabolic Panel (CMP)
│   └── Includes LFTs: AST, ALT, ALP, Bilirubin
├── Testosterone, Total
├── Estradiol (if on E2 therapy)
├── CBC with differential
└── Lipid panel (baseline, then annually)

After stable on therapy (6+ months):
├── CMP with LFTs: Every 6 months
├── Hormone levels: Every 6-12 months
└── Lipid panel: Annually

Prostate Cancer Panel:

Baseline:
├── PSA
├── CMP with LFTs
├── CBC
├── Testosterone (to confirm castrate levels with LHRH)
└── Comprehensive staging labs per oncology

Monitoring:
├── PSA: Per oncology protocol (often monthly initially)
├── LFTs: Monthly x 4, then quarterly
├── CBC: Every 3 months
└── Testosterone: To confirm castrate levels

11. Cost and Availability

Brand and Generic Availability

Brand Name:

• Casodex (AstraZeneca) - original brand, still marketed

Generic Availability:

• Available since 2009 (patent expiration)
• Multiple generic manufacturers
• Significant cost reduction with generics

Typical Pricing (United States, 2024)

Generic Bicalutamide 50 mg (30 tablets):

• Retail: $15-50
• With GoodRx/discount card: $8-20
• Generic pricing highly variable by pharmacy

Brand Casodex 50 mg (30 tablets):

• AWP: ~$900-1,200
• Rarely dispensed due to generic availability

Insurance Coverage

Commercial Insurance:

• Generally covered for FDA-approved indication (prostate cancer)
• May require prior authorization
• Off-label use (transgender therapy) coverage variable

Medicare Part D:

• Covered for prostate cancer indication
• Generic preferred tier
• Off-label coverage rare

Medicaid:

• State-dependent coverage policies
• Generally covers generic for approved indications

International Availability

Global Status:

• WHO Essential Medicines List
• Available worldwide
• Generic availability in most countries
• Brand names vary by country (Casodex most common)

Pricing Comparison:

• Generally lower cost outside United States
• Widely available in generic form globally

Patient Assistance Programs

AstraZeneca Patient Assistance:

• Available for uninsured/underinsured patients
• Applies to brand Casodex
• Income requirements apply

Generic Assistance:

• Various pharmacy discount programs
• Cost already low for generic

12. Clinical Evidence Summary

Pivotal Prostate Cancer Trials

Combined Androgen Blockade Studies:

Multiple randomized controlled trials established bicalutamide's efficacy in metastatic prostate cancer:

• Combination with LHRH analogs superior to LHRH analog alone
• PSA response rates of 80-90% in hormone-sensitive disease
• Median survival improvements documented in meta-analyses

Early Prostate Cancer (EPC) Program:

Three large randomized trials (Studies 23, 24, 25) evaluated bicalutamide 150 mg:

• Over 8,000 patients enrolled
• Showed benefit in locally advanced disease
• No survival benefit in localized disease
• FDA declined approval for this indication
• Cardiovascular concerns in localized disease arm

Comparison Studies

Bicalutamide vs. Flutamide:

• Similar efficacy in PSA response
• Bicalutamide better tolerated (less GI toxicity)
• Less hepatotoxicity with bicalutamide
• Once-daily dosing advantage for bicalutamide

Bicalutamide vs. Castration:

• Monotherapy studies showed similar efficacy
• Quality of life advantages with monotherapy (preserved sexual function)
• More gynecomastia with bicalutamide monotherapy

Transgender Medicine Evidence

Early Studies (2019):

• Neyman et al.: 23 transgender adolescents
• Liver enzymes remained normal in those tested
• No apparent adverse effects reported
• Noted as preliminary data

2024 Research:

• Case series of 24 transgender adults
• Median ALT 20 (13-29) IU/L (within normal limits)
• No signal of hepatotoxicity
• One grade 1 toxicity in setting of intercurrent condition
• Retrospective cohort: No increased transaminases vs. other antiandrogens

Single Hepatotoxicity Case Report (2024):

• Transgender female adolescent on 50 mg daily
• Presented with liver toxicity
• Resolved after discontinuation
• First documented case in transgender population
• Emphasizes need for monitoring despite reassuring cohort data

Meta-Analyses

Prostate Cancer Combined Androgen Blockade:

• Meta-analyses support modest survival benefit
• Combined therapy vs. castration alone: ~3-5% improvement at 5 years
• Toxicity considerations in therapy selection

12A. Protocol Integration

Combined Androgen Blockade (CAB) Protocols

Definition: Combined Androgen Blockade (CAB), also known as Maximal Androgen Blockade (MAB), refers to the simultaneous use of an LHRH analog (medical castration) plus a peripheral antiandrogen like bicalutamide.

Rationale for CAB:

1. LHRH analogs suppress testicular testosterone (~95% of circulating T)
2. Adrenal androgens (DHEA, androstenedione) continue at ~5% of total
3. Peripheral antiandrogen blocks remaining androgens at receptor level
4. Prevents testosterone "flare" when initiating LHRH analog

Prostate Cancer CAB Protocols

Standard CAB Protocol (Metastatic Disease):

LHRH Analog Options for CAB:

CAB Protocol Monitoring:

Week 0:   Baseline PSA, testosterone, LFTs, imaging
Week 2:   LFTs (hepatotoxicity window)
Week 4:   PSA, testosterone, LFTs
Week 8:   PSA, LFTs
Week 12:  PSA, testosterone (confirm castrate <50 ng/dL), LFTs
Month 4+: PSA monthly, LFTs quarterly, testosterone quarterly

Testosterone Flare Prevention:

When using LHRH agonists (not antagonists), initial testosterone surge occurs:

• Day 1-3: Testosterone begins rising
• Day 7-14: Peak flare (can be 50-100% above baseline)
• Week 3-4: Decline below baseline
• Week 4-6: Castrate levels achieved

Flare Clinical Consequences (Without Antiandrogen):

• Bone pain exacerbation
• Urinary obstruction worsening
• Spinal cord compression risk (bone mets)
• Tumor flare phenomenon

Bicalutamide as Flare Cover:

• Start 7 days before LHRH agonist (or simultaneously)
• Continue for at least 4 weeks
• May discontinue after castrate levels confirmed (some protocols)
• Or continue as part of CAB (standard approach)

Feminizing HRT Protocol Integration

Bicalutamide in Feminizing Regimens:

Bicalutamide is typically used as one component of a multi-agent feminizing protocol.

Protocol Options:

Protocol 1: Estrogen + Bicalutamide (Most Common)

Timeline:

Month 0:    Start estradiol low dose
Month 1:    Add bicalutamide 25 mg after baseline LFTs
Month 2:    Titrate estradiol based on levels; check LFTs
Month 3:    Consider bicalutamide 50 mg if needed; LFTs
Month 4-6:  Stabilize doses based on response and labs
Month 6+:   Maintenance with less frequent monitoring

Protocol 2: Bicalutamide Monotherapy (Selected Patients)

Monotherapy Considerations:

• Testosterone rises paradoxically (blocks negative feedback)
• Gynecomastia very common (elevated E2 from aromatization)
• Breast development occurs but slower than with E2
• Sexual function may be better preserved
• Fertility maintained (sperm production continues)

Protocol 3: Maximal Suppression (E2 + GnRH Analog + Bicalutamide)

Reserved for:

• Insufficient T suppression with E2 + Bica
• Pre-operative suppression
• Specific clinical requirements

Protocol Comparison Matrix

Transition Between Protocols

From Bicalutamide to GnRH Analog:

Scenario: Patient on E2 + Bica with inadequate T suppression
Week 0:  Continue current regimen; order GnRH analog
Week 1:  Add GnRH analog; continue bicalutamide (flare cover)
Week 4:  Check testosterone; expect declining
Week 8:  If T castrate, may consider stopping bicalutamide
Week 12: Confirm sustained suppression; final decision on bicalutamide

From Bicalutamide to Orchiectomy:

Scenario: Patient proceeding to surgical castration
Pre-op:  Continue bicalutamide until surgery
Day 0:   Orchiectomy performed
Post-op: May discontinue bicalutamide (no testosterone to block)
         OR continue 2-4 weeks (adrenal androgen coverage)
Week 4:  Check testosterone; should be castrate
         Discontinue bicalutamide if levels castrate

Protocol Selection Algorithm

Step 1: Determine Primary Goal
├── Prostate Cancer → CAB Protocol (FDA-approved)
├── Feminizing HRT → Continue to Step 2
└── Hirsutism → Low-dose monotherapy or E2 + Bica

Step 2: Feminizing HRT - Assess Factors
├── Fertility desired now?
│   ├── Yes → Bicalutamide monotherapy
│   └── No → Continue to Step 3
├── Estrogen contraindicated?
│   ├── Yes → Bicalutamide monotherapy
│   └── No → E2 + Bicalutamide
└── Prior inadequate suppression?
    ├── Yes → E2 + GnRH +/- Bica
    └── No → E2 + Bicalutamide

Step 3: Hepatic Risk Assessment
├── Elevated baseline LFTs → Consider spironolactone instead
├── Hepatotoxic comedications → Enhanced monitoring or alternative
└── Normal baseline → Standard E2 + Bica protocol

Protocol-Specific Monitoring

CAB (Prostate Cancer):

E2 + Bicalutamide (Feminizing HRT):

13. Comparison with Alternatives

First-Generation NSAAs

Second-Generation NSAAs (Enzalutamide, Apalutamide, Darolutamide)

Key Differences:

• Second-generation agents more potent AR antagonists
• Additional mechanisms (block nuclear translocation, DNA binding)
• FDA-approved for castration-resistant prostate cancer (CRPC)
• Significantly higher cost
• Different indication (metastatic CRPC, non-metastatic CRPC)

When to Use Second-Generation:

• Disease progression on first-generation antiandrogen
• Castration-resistant prostate cancer
• Certain high-risk disease settings

Steroidal Antiandrogens

Bicalutamide vs. Cyproterone Acetate:

Bicalutamide vs. Spironolactone:

GnRH Agonists/Antagonists

Role Comparison:

• GnRH analogs: Suppress testosterone production centrally
• Bicalutamide: Blocks testosterone action peripherally
• Combination therapy: Maximal androgen blockade
• GnRH analogs often preferred in transgender therapy for complete suppression

14. Storage and Handling

Storage Requirements

Temperature:

• Store at controlled room temperature: 20-25°C (68-77°F)
• Excursions permitted: 15-30°C (59-86°F)

Environment:

• Protect from moisture
• Keep in original container until use
• Keep container tightly closed

Light:

• No specific light protection required
• Standard packaging adequate

Handling Precautions

Healthcare Workers:

• Standard handling precautions for oral medications
• No special hazardous drug handling required per NIOSH 2016 list
• Gloves recommended for frequent handling

Pregnancy Exposure:

• Women who are or may become pregnant should not handle crushed/broken tablets
• Intact tablets may be handled with minimal risk
• If exposure occurs, wash hands thoroughly

Dispensing Considerations

Packaging:

• Available in bottles of 30, 100 tablets
• Some manufacturers offer blister packaging
• Protect from humidity in multi-dose containers

Tablet Integrity:

• Do not crush or break tablets
• Tablets should be swallowed whole
• If patient cannot swallow whole tablets, consult pharmacist

Stability

Expiration:

• Typical shelf life: 2-3 years from manufacture
• Use by date on packaging should be observed
• No specific stability concerns under normal conditions

After Opening:

• Once opened, use within expiration date
• No requirement to discard after specific time post-opening
• Maintain original container closure between uses

15. References

Primary Literature

1. FDA Prescribing Information. Casodex (bicalutamide) tablets. AstraZeneca. Revised 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf

2. Angus LM, Hong QV, Cheung AS, Nolan BJ. Effect of bicalutamide on serum total testosterone concentration in transgender adults: a case series. Therapeutic Advances in Endocrinology and Metabolism. 2024;15:20420188241305022.

3. Neyman A, Fuqua JS, Eugster EA. Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents. J Adolesc Health. 2019;64(4):544-546.

4. Journal of Adolescent Health. Bicalutamide-Induced Hepatotoxicity in a Transgender Male-to-Female Adolescent. 2024.

5. Journal of Adolescent Health. Placing a Report of Bicalutamide-Induced Hepatotoxicity in the Context of Current Standards of Care for Transgender Adolescents. 2024.

Clinical Guidelines

6. WPATH Standards of Care, Version 8 (SOC8). World Professional Association for Transgender Health. 2022.

7. Hembree WC, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(11):3869-3903.

8. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. National Comprehensive Cancer Network. 2024.

Pharmacology References

9. Kolvenbag GJ, Blackledge GR. Worldwide activity and safety of bicalutamide: a summary review. Urology. 1996;47(1A Suppl):70-79.

10. Furr BJ, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology. 1996;47(1A Suppl):13-25.

Comparative Studies

11. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. PMC. 2018.

12. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database. PMC. 2018.

Additional Resources

13. Transfeminine Science. Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy. Available at: https://transfemscience.org/articles/bica-adoption/

14. UCSF Gender Affirming Health Program. Overview of feminizing hormone therapy. Available at: https://transcare.ucsf.edu/guidelines/feminizing-hormone-therapy

15. National Cancer Institute. Bicalutamide Drug Information. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/bicalutamide

Document Completion: 2025-12-26 Status: PAPER 55 OF 76 COMPLETE Next Paper: #56 - Flutamide